Healthcare and AI: A complete check-up
The Sustainable Market Strategies team’s latest report examines the impact of AI in healthcare, which is growing at a rapid pace but is bringing about significant cause for concern. One major issue is bias, with AI risking exacerbating existing health disparities when trained on data that lack diversity. There are also worries around safety, privacy and security, loss of personal interaction and job displacement. As it stands, regulation of AI in healthcare is very limited, but this will grow over time. The companies that will be best positioned for the future will be those that proactively engage with regulators to shape effective and fair AI policies. Although concerns are valid, the healthcare sector stands to benefit the most positively from AI. Potential winners include Sysmex, Fresenius, Hologic and Intuitive Surgical.
Edition: 187
- 31 May, 2024
SAP (SAP GR) Germany
Technology
SAP is guiding for cloud revenues to reach €14.1bn (+25% Y/Y) in FY23, suggesting growth will be far stronger in H2 vs. H1, in total contradiction with the current economic slowdown and competitors’ recent comments. Pierre-Olivier Essig struggles to share management’s bullishness which has led to him downgrading the stock to Sell (from Buy). His new TP is €100 (previously €140).
AIR continues to boast an enviable track record with impressive gains on Buy-rated stocks including Aixtron, Meier Tobler, Novo Nordisk and Rolls-Royce, as well as shorts including Fresenius Medical Care and Grifols.
Edition: 171
- 13 October, 2023
Fresenius SE (FRE GR) & Fresenius Medical (FME GR) Germany
Healthcare
Elliott has taken a stake in Fresenius SE, but the company’s top shareholder, the Else Kroner Foundation, is an obstacle to immediate value creation, a source told CTFN. As Elliott faces down the foundation, the activist could force a breakup of Fresenius Medical, a partially owned subsidiary of the company, or agitate for equity-dilutive M&A by subsidiary Kabi to improve its market share in the US. Bankers are already pitching the firm’s components to potential private-equity bidders, with subsidiary Vamed proving the toughest sell, the source said. Click here for the full story.
Edition: 148
- 11 November, 2022